Supplementary Figure S5 from Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity

Jones, Trace M.; Espitia, Claudia M.; Chipollini, Juan; Lee, Benjamin R.; Wertheim, Jason A.; Carew, Jennifer S.; Nawrocki, Steffan T.

doi:10.1158/2767-9764.22546286.v1

crc-22-0340-s05.pdf (107.2 kB)

Supplementary Figure S5 from Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity

journal contribution

posted on 2023-04-04, 02:03 authored by Trace M. Jones, Claudia M. Espitia, Juan Chipollini, Benjamin R. Lee, Jason A. Wertheim, Jennifer S. Carew, Steffan T. Nawrocki

Quantification of IHC staining.

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

Cisplatin therapy is associated with significant nephrotoxicity, which limits its clinical use. Here we demonstrate that NEDDylation inhibition with pevonedistat is a novel approach to selectively prevent cisplatin-induced oxidative damage to the kidneys while simultaneously enhancing its anticancer efficacy. Clinical evaluation of the combination of pevonedistat and cisplatin is warranted.